"In our latest IPWatchdog Unleashed podcast, I spoke with Rob Sahr, shareholder at Wolf Greenfield and co-chair of our 2025 Life Sciences Masters™ program. Our conversation zeroed in on a hard truth the public rarely sees: moving a molecule from early discovery to an FDA-approved therapy requires a chain of scientific and economic miracles-and every one of them leans on a reliable patent system."
"Rob's journey from neuroscience PhD to law student to patent attorney is a testament to the deep interplay between science and law in the biopharmaceutical industry. Inspired by a course titled "Brain the Final Frontier" during his time at SUNY Albany, Rob's passion for neuroscience ignited, fueling his future transition into the pharmaceutical realm and eventually into patent law. Rob's path through the life sciences industry underscores the myriad challenges and triumphs involved, and"
Moving a molecule from discovery to FDA approval requires successive scientific and economic successes, each dependent on substantial capital and legal certainty. The patent system provides incentives for investors by protecting exclusivity, mitigating risk across long development timelines. Challenges include double patenting rules, the role of government funding, judicial uncertainty, and shifting policy that can undermine predictability. Translating scientific training into intellectual property practice bridges laboratory insight with legal strategy to protect inventions and attract investment. Drug development demands coordinated milestones—preclinical validation, candidate selection, clinical trials, and regulatory approval—where failures at any stage can halt progress and waste capital.
Read at IPWatchdog.com | Patents & Intellectual Property Law
Unable to calculate read time
Collection
[
|
...
]